Study index
340+
Oncology trials — live
27
Registered bioregulator studies
2,774
Enrollment slots
FDAAA 801
Federal registration
Oncology trials indexed live. Bioregulator studies registered and operating.
ClinicalTrials.gov v2 API supplies oncology trial data on every match request. The 27 Atumnus-registered observational studies are filed under FDAAA 801, IRB-approved.
Oncology trials
Urologic malignancies — currently recruiting
| Indication | Trial | Biomarker requirement | Phase | Status |
|---|---|---|---|---|
| mCRPC | Prostate — AR pathway inhibitor combination | AR-V7, BRCA1/2 | Phase II | Recruiting |
| Urothelial carcinoma | Bladder — FGFR3 targeted therapy | FGFR3 alteration | Phase II | Recruiting |
| Clear cell RCC | RCC — HIF-2α inhibitor expansion | VHL mutation | Phase II | Recruiting |
| BRCA1/2 mCRPC | Prostate — PARP inhibitor + checkpoint | HRR gene panel | Phase I/II | Recruiting |
| MIBC | Bladder — neoadjuvant combination | FGFR3, TP53 | Phase II | Recruiting |
| Advanced RCC | RCC — dual checkpoint blockade | PD-L1, PBRM1 | Phase III | Recruiting |
Showing 6 of 340+ recruiting trials. Full index available to credentialed physicians and lab partners.
Matching architecture
Four-component pipeline. Patient summary to ranked trial list in under one second.
Ranking model
TrialSpace
Patient clinical summaries and trial target populations embedded in shared vector space. Narrows 340+ trials to top 20 in under one second. 32,768 token context window.
Classification model
TrialChecker
Binary patient-trial eligibility classification. Criterion by criterion — age range, mutation status, prior therapy lines, organ function thresholds. AUROC 0.94–0.98 on real EHR data at Dana-Farber.
Data source
ClinicalTrials.gov v2 API
All trial data pulled live on every match request. No internal database. Trial updates and closure reflected immediately.
Privacy
On-operator inference
Models run inside operator network. No PHI transmitted. Trained on synthetic EHR data. No BAA with any model vendor required.
Bioregulator studies
27 registered observational studies. IRB-approved. Enrollment opens Q3 2026.
Atumnus LLC. ClinicalTrials.gov. FDAAA 801. Each study covers a peptide bioregulator compound with characterized mechanism in peer-reviewed literature.
| Compound | Studies | Enrollment | Indication | Mechanism (literature-grounded) |
|---|---|---|---|---|
| BPC-157 | 4 | Q3 2026 | Musculoskeletal regeneration, gut mucosa repair | GH receptor modulation, NO pathway, angiogenesis |
| MOTS-c | 3 | Q3 2026 | Metabolic function, mitochondrial health | AMPK activation, mitochondrial biogenesis |
| Epithalon | 4 | Q3 2026 | Telomere biology, circadian regulation | Telomerase activation, melatonin pathway |
| Semax | 3 | Q3 2026 | Neuroprotection, cognitive function | BDNF/NGF upregulation, dopaminergic modulation |
| KPV | 3 | Q3 2026 | Inflammation, mucosal repair | MC1R agonism, NF-κB suppression |
| Additional compounds | 10 | Q3 2026 | See registry for full compound list | Various — filed per protocol |
Study index access
NCT numbers, eligibility criteria, and enrollment documentation are available to credentialed physicians and lab partners. Sponsor inquiries include indication, phase, and enrollment target.